Literature DB >> 12094867

Current liver biopsy practices for suspected parenchymal liver diseases in the United States: the evolving role of radiologists.

Terence L Angtuaco1, Sunil K Lal, Geraldine D Banaad-Omiotek, Syed S A Zaidi, Colin W Howden.   

Abstract

OBJECTIVE: The aim of this study was to determine current liver biopsy practices in the United States.
METHODS: We mailed a questionnaire to 260 randomly selected members of the American Association for the Study of Liver Diseases. Statistical analysis was conducted using the chi2 test.
RESULTS: A total of 128 members (49%) responded, with 106 responses suitable for inclusion. Of the respondents, 25% had a radiologist perform >50% of their patients' liver biopsies, whereas 38% personally performed all their patients' biopsies. During training, 87% of respondents were taught to perform liver biopsy using the "blind" technique, 2% with ultrasound (US) guidance, and 11% both. A total of 76% used US guidance during liver biopsy. More private practitioners than those practicing in academic centers used the "blind" technique (35% vs 18%; p = 0.02) and referred >50% of their patients for liver biopsy to Radiology (36% vs 17%; p = 0.01); desire for real-time US guidance was the main reason in 43% of cases. Of the respondents, 75% used US for safety reasons; 77% of those who did not use US believed that it was unnecessary. Overall, 87% of respondents indicated that patient safety was the most important issue during liver biopsy; only 2% thought that personal convenience and cost-effectiveness were most important.
CONCLUSIONS: Respondents' chief concern was patient safety, and most used US for this reason. Private practitioners were less likely than those practicing in academic centers to use US guidance and were more likely to refer patients to Radiology.

Entities:  

Mesh:

Year:  2002        PMID: 12094867     DOI: 10.1111/j.1572-0241.2002.05788.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  9 in total

1.  Trends in the indication and method of liver biopsy for hepatitis B and C.

Authors:  Michael J Lipp; Lionel S D'Souza; David J Clain; Henry C Bodenheimer; Albert D Min
Journal:  Dig Dis Sci       Date:  2010-07-15       Impact factor: 3.199

2.  Outpatient liver biopsy: a prospective evaluation of 500 cases.

Authors:  P Beddy; I L Lyburn; T Geoghegan; O Buckley; A R Buckley; W C Torreggiani
Journal:  Gut       Date:  2006-10-06       Impact factor: 23.059

3.  Percutaneous liver biopsy practice patterns among Canadian hepatologists.

Authors:  Mohammed Aljawad; Eric M Yoshida; Julia Uhanova; Paul Marotta; Natasha Chandok
Journal:  Can J Gastroenterol       Date:  2013-11       Impact factor: 3.522

4.  Who should be performing liver biopsies?

Authors:  C N Ghent
Journal:  Can J Gastroenterol       Date:  2009-06       Impact factor: 3.522

Review 5.  Feasibility and experience of nurse-led ultrasound-guided percutaneous liver biopsy.

Authors:  Elizabeth Anne Farrington; Giles Maskell; Hyder Syed Hussaini
Journal:  Frontline Gastroenterol       Date:  2012-04-13

6.  Liver biopsy for parenchymal liver disease - is routine real time image guidance unnecessary?

Authors:  Anil John; Saad Al Kaabi; Madiha Emran Soofi; Muneera Mohannadi; Salva Manam Kandath; Moataz Derbala; Rafie Yakoub; Esra Mohammed Al-Ahdal; Manik Sharma; Hamid Wani; Nazeeh Dweik; Anjum John; Mohammed Tariq Butt
Journal:  Indian J Gastroenterol       Date:  2013-09-19

Review 7.  Controversies in liver biopsy: who, where, when, how, why?

Authors:  Lawrence S Friedman
Journal:  Curr Gastroenterol Rep       Date:  2004-02

8.  Liver biopsies for chronic hepatitis C: should nonultrasound-guided biopsies be abandoned?

Authors:  J A Flemming; D J Hurlbut; B Mussari; L C Hookey
Journal:  Can J Gastroenterol       Date:  2009-06       Impact factor: 3.522

Review 9.  Liver biopsy for histological assessment: The case against.

Authors:  Faisal M Sanai; Emmet B Keeffe
Journal:  Saudi J Gastroenterol       Date:  2010 Apr-Jun       Impact factor: 2.485

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.